<DOC>
	<DOCNO>NCT01741181</DOCNO>
	<brief_summary>Background Objectives : The presence vitamin D deficiency patient type 2 diabetes mellitus ( T2DM ) associate increase risk cardiovascular disease ( CVD ) . We aim see whether supplementation vitamin D patient help improve endothelial function ( EF ) surrogate marker CVD risk . Hypothesis : Vitamin D supplementation patient T2DM low serum 25 ( OH ) D concentration ( &lt; 30ng/ml ) improve EF measure Endo-PAT machine 0.4 unit ( 30 % improvement baseline ) and/or result increase EPCs ( CD133+/KDR+ ) CD45dim CD34+/KDR . The investigator test hypothesis compare 2 group T2DM patient randomize placebo vitamin D3 16 week . Methods : This 16 week trial 120 T2DM patient screen aim recruit 60 T2DM patient vitamin D deficiency insufficiency . Out 60 patient , 30 patient start vitamin D supplementation 30 patient give matched placebo . Endothelial function ( EF ) check supplementation see change EF . Significance Project : If study show significant improvement EF , would justify large scale study show vitamin D supplementation patient T2DM mitigate CVD risk vitamin D supplementation patient T2DM vitamin D deficiency improve CVD risk .</brief_summary>
	<brief_title>Vitamin D Supplementation Patients With Diabetes Mellitus Type 2</brief_title>
	<detailed_description>Overall Aims : Type 2 Diabetes Mellitus ( T2DM ) increasingly prevalent Singapore high cardiovascular disease ( CVD ) risk factor ( 1,2 ) . The presence low serum 25 ( OH ) D concentration ( &lt; 30ng/ml ) also classify independent predictor CVD ( 3,4 ) see prevalent T2DM ( 5-7 ) . We aim see whether replacement vitamin D patient help mitigate CVD risk . Since endothelial dysfunction one early manifestation CVD robust surrogate marker , aim measure endothelial function ( EF ) vitamin D supplementation evaluate beneficial impact endpoint . Specific Aims : Although , small scale study do single high dose replacement vitamin D2/D3 , study do use regular daily supplementation vitamin D3 measurement EF use Endo-PAT machine measurement endothelial progenitor cell ( EPCs ) .We pilot study see whether replacement vitamin D result improvement EF measure use Endo-PAT estimation EPCs biomarkers independent establish surrogate marker CVD risk . The estimation endothelial progenitor cell propose surrogate marker vascular dysfunction know reduced patient cardiovascular risk factor ( 8 ) . The . circulate endothelial cell ( CECs ) endothelial microparticles see elevated patient cardiovascular risk factor DM also propose effective surrogate marker . We aim quantify . endothelial progenitor cell ( EPCs ) stain positive CD133+/KDR ( kinase insert domain-containing receptor ) , CD34+/KDR CD45dim CD34+/KDR , CECs ( CD 146+/CD45- ) EMPs derive endothelial progenitor ( CD45−/CD146+/CD34+/CD117+ ) mature endothelial cell ( CD45−/CD146+/CD34+/CD117− ) .using flow cytometry . Primary Hypothesis : Vitamin D supplementation patient T2DM low serum 25 ( OH ) D concentration ( &lt; 30ng/ml ) improve EF measure Endo-PAT machine 0.4 unit ( 30 % improvement baseline ) and/or result increase EPCs ( CD133+/KDR+ ) CD45dim CD34+/KDR . The investigator test hypothesis compare 2 group T2DM patient randomize placebo vitamin D3 16 week . Secondary Objectives : To explore prevalence low serum 25 ( OH ) D concentration ( &lt; 30ng/ml ) T2DM patient evaluate difference EF two group . To see whether vitamin D supplementation help improve parameter biomarkers , blood pressure , BMI , urine albumin-to-creatinine ratio ( ACR ) , lipid profile T2DM patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Subjects Type 2 Diabetes Mellitus HbA1c : 6.010.0 % Male female age 2180 year Stable Diabetes , blood pressure hyperlipidemia medication ( 25 % dose adjustment allow ) last three month Baseline serum 25 ( 0H ) D concentration &lt; 30ng/ml randomisation Baseline serum 25 ( OH ) D concentration &gt; 30ng/ml Baseline HbA1c &gt; 10.1 % Baseline hypercalcemia ( Ca &gt; 2.58 mmol/L ) Known case Primary Hyperparathyroidism Known bisphosphonates Known Vitamin D supplementation 1000 unit daily last one year . Chronic renal failure eGFR &lt; 30ml/min Known cirrhosis liver transaminitis ALT/AST &gt; 3X ULN Patients h/o sarcoidosis , renal calculus malignancy Patients current treatment tuberculosis Pregnancy Lactation Women childbearing potential take effective contraceptive measure . Patients long term glucocorticoid antiretroviral drug Patients orlistat counter preparation claim block fat absorption . A change type medication hypertension , diabetes mellitus hyperlipidemia last three month Patients undergone form bariatric surgery Patients know malabsorption disorder Patients know osteoporosis baseline BMD scan show osteoporosis T score &lt; 2.5SD ( randomisation )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>25 ( OH ) Vitamin D</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Endothelial Function</keyword>
</DOC>